These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

49 related articles for article (PubMed ID: 7109922)

  • 1. [Study on the effect and tolerance of Acelate as an aldosterone antagonist].
    Babej RM
    Med Welt; 1982 Jun; 33(22):834-6. PubMed ID: 7109922
    [No Abstract]   [Full Text] [Related]  

  • 2. [Use of aldactone and veroshpiron in complex therapy of patients with circulation disorders].
    Bezborod'ko BN; Shekhunova MI; Selivonenko VG
    Ter Arkh; 1973 Jan; 45(1):84-6. PubMed ID: 4770028
    [No Abstract]   [Full Text] [Related]  

  • 3. [New clinical application of spironolactone].
    Fukuchi S
    Nihon Rinsho; 1974 Nov; 32(11):3326-32. PubMed ID: 4615183
    [No Abstract]   [Full Text] [Related]  

  • 4. [Use of mefruside (Baycaron) in edema and hypertension with special reference to water-electrolyte balance].
    Ravetta A
    Minerva Cardioangiol; 1973 Mar; 21(3):231-40. PubMed ID: 4708942
    [No Abstract]   [Full Text] [Related]  

  • 5. [Hypotensive effect of spironolactone in patients with essential hypertension and aldosterone regulation disorders].
    Wambach G; Helber A; Bönner G; Hummerich W; Meurer KA; Kaufmann W
    Med Welt; 1980 Aug; 31(31-32):1135-7. PubMed ID: 7421547
    [No Abstract]   [Full Text] [Related]  

  • 6. Does aldosterone-to-renin ratio predict the antihypertensive effect of the aldosterone antagonist spironolactone?
    Mahmud A; Mahgoub M; Hall M; Feely J
    Am J Hypertens; 2005 Dec; 18(12 Pt 1):1631-5. PubMed ID: 16364838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment of refractory ascites with clonidine and spironolactone].
    Lenaerts A; Van Cauter J; Moukaiber H; Meunier JC; Ligny G
    Gastroenterol Clin Biol; 1997; 21(6-7):524-5. PubMed ID: 9295984
    [No Abstract]   [Full Text] [Related]  

  • 8. Efficacy of add-on aldosterone receptor blocker in uncontrolled hypertension.
    Sharabi Y; Adler E; Shamis A; Nussinovitch N; Markovitz A; Grossman E
    Am J Hypertens; 2006 Jul; 19(7):750-5. PubMed ID: 16814132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Therapeutic methods].
    Arq Bras Cardiol; 1966 Oct; 19():Suppl 1:67-70. PubMed ID: 5994227
    [No Abstract]   [Full Text] [Related]  

  • 10. The spironolactone, amiloride, losartan, and thiazide (SALT) double-blind crossover trial in patients with low-renin hypertension and elevated aldosterone-renin ratio.
    Hood SJ; Taylor KP; Ashby MJ; Brown MJ
    Circulation; 2007 Jul; 116(3):268-75. PubMed ID: 17606839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical experience with Dytac.
    Weber JC
    Minerva Med; 1963 Oct; 54(81 Suppl):2996-7. PubMed ID: 5877330
    [No Abstract]   [Full Text] [Related]  

  • 12. Polythiazide in the treatment of the elderly and the aged.
    Kountz WB; Kheim T; Ackermann PG
    Geriatrics; 1965 Dec; 20(12):1016-22. PubMed ID: 5842249
    [No Abstract]   [Full Text] [Related]  

  • 13. Effects of clonidine on diuretic response in ascitic patients with cirrhosis and activation of sympathetic nervous system.
    Lenaerts A; Codden T; Meunier JC; Henry JP; Ligny G
    Hepatology; 2006 Oct; 44(4):844-9. PubMed ID: 17006921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of long-term treatment with spironolactone on variceal pressure in patients with portal hypertension without ascites.
    Nevens F; Lijnen P; VanBilloen H; Fevery J
    Hepatology; 1996 May; 23(5):1047-52. PubMed ID: 8621132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Biological factors influencing response to diuretics in patients with cirrhosis and ascites].
    Lenaerts A; Codden T; Henry JP; Van Cauter J; Meunier JC; Ligny G
    Gastroenterol Clin Biol; 2001 Mar; 25(3):268-72. PubMed ID: 11395674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spironolactone responsive familial hypertension. A potentially high prevalence of mineralocorticoid disease in Oman.
    Woodhouse NJ; Elshafie OT; Mehar A; Johnston WJ; Al-Kaabi JM
    Saudi Med J; 2003 Feb; 24(2):229-31. PubMed ID: 12682699
    [No Abstract]   [Full Text] [Related]  

  • 17. Aldosterone antagonism in addition to angiotensin-converting enzyme inhibitors in heart failure.
    Bauersachs J; Fraccarollo D
    Minerva Cardioangiol; 2003 Apr; 51(2):155-64. PubMed ID: 12783071
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aldactide and dytide.
    Drug Ther Bull; 1967 Oct; 5(21):82-3. PubMed ID: 6077512
    [No Abstract]   [Full Text] [Related]  

  • 19. Transcardiac gradient of aldosterone before and after spironolactone in patients with congestive heart failure.
    Tsutamoto T; Wada A; Maeda K; Hayashi M; Tsutsui T; Ohnishi M; Fujii M; Matsumoto T; Yamamoto T; Takayama T; Ishii C
    J Cardiovasc Pharmacol; 2003 Jan; 41 Suppl 1():S19-22. PubMed ID: 12688391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker.
    Chrysostomou A; Pedagogos E; MacGregor L; Becker GJ
    Clin J Am Soc Nephrol; 2006 Mar; 1(2):256-62. PubMed ID: 17699214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.